Literature DB >> 2289180

Sexual abuse in the developmentally disabled: dilemmas of diagnosis.

S L Elvik1, C D Berkowitz, E Nicholas, J L Lipman, S H Inkelis.   

Abstract

Evaluation of developmentally disabled persons for physical signs of sexual abuse presents many challenges to the practitioner. This group is especially vulnerable to all types of abuse. A group of 35 mentally retarded females from a residential treatment facility was examined by the child abuse medical team at Harbor/UCLA Medical Center after one inpatient was found to be pregnant. Patients ranged in age from 13 to 55 years (median, 26 years; mean, 31.3 +/- 13.6 years). All of the women had some degree of disability, with 24 (69%) being categorized as profoundly retarded. No patient was able to provide a history. There were 13 (37%) patients who had genital findings we believe are consistent with prior vaginal penetration. Dilemmas which arose during evaluation included the significance of healed genital lesions in this population and the implications of the findings for the residential facility. While developmentally disabled persons need an advocate in the medical and legal systems, these patients can overwhelm the practitioner. Whenever possible, a team approach is recommended to decrease the work load and frustration and provide collegial support and affirmation of findings.

Entities:  

Mesh:

Year:  1990        PMID: 2289180     DOI: 10.1016/0145-2134(90)90098-e

Source DB:  PubMed          Journal:  Child Abuse Negl        ISSN: 0145-2134


  2 in total

1.  Is it possible to assess the impact of abuse on children with pervasive developmental disorders?

Authors:  P Howlin; J Clements
Journal:  J Autism Dev Disord       Date:  1995-08

Review 2.  Prevalence of Sexual Abuse in Adults with Intellectual Disability: Systematic Review and Meta-Analysis.

Authors:  Raluca Tomsa; Smaranda Gutu; Daniel Cojocaru; Belén Gutiérrez-Bermejo; Noelia Flores; Cristina Jenaro
Journal:  Int J Environ Res Public Health       Date:  2021-02-18       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.